CHCWM – Cancer & Hematology Centers of West Michigan

REGN3767-ONC-1613 (Regeneron)

Description:  Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-In-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Lag 3 inhibitor) Administered Alone or in Combination with REGN2810 (PD-1 inhibitor) in Patients with Advanced Malignancies. 

Mechanism of Action:  Anti-LAG-3 antibody +/Cemiplimab (PD-1 blockade) (combination immune checkpoint inhibition)

Target Patient Population: Currently enrolling expansion cohorts in PD-1 naïve metastatic melanoma  and metastatic Cutaneous Squamous Cell Cancers (PD1 experienced/naïve)

Study Design:  Drug is administered IV every 3 weeks.